title: Autologous blood stem cell transplantation as intensive consolidation therapy in hematological malignancies.
abstract: Ten consecutive patients (pts), suffering from hematological malignancies (5 NHL, 3 ANLL and 2 HD), received high doses of radio-chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation. Seven of them were in 1st CR, two in 3rd CR and one in refractory status. The recruitment of PBSC was performed during the conventional non-intensive schedule of therapy. The median interval between the remission and the transplant was 6 months (3-15). The pts received a median of 0.96 x10(9) MNC/Kg b.w. and of 3.8 x10(4) CFU-GM/Kg b.w. Hemopoietic recovery occurred promptly and the median number of days to reach WBC greater than 1.0 x10(9)/L was 10 (7-15), PMN greater than 0.5 x10(9)/L was 12 (10-34), platelets greater than 50 x10(9)/L was 13 (10-41) and reticulocytes greater than 20 x10(9)/L was 12 (10-15). Three pts relapsed after 14, 12 and 6 months, respectively. Two of them achieved a further remission and one died. The remaining seven, are alive and disease-free with a follow-up of 11 months (range 2-27).
authors.affiliation: Divisione di Ematologia e Centro Trasfusionale, Ospedale Civile, Pescara, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Fioritoni
authors.forename: A
authors.initials: A
authors.lastname: Iacone
authors.forename: D
authors.initials: D
authors.lastname: D'Antonio
authors.forename: A
authors.initials: A
authors.lastname: Dragani
authors.forename: A M
authors.initials: AM
authors.lastname: Quaglietta
authors.forename: P
authors.initials: P
authors.lastname: Accorsi
authors.forename: A
authors.initials: A
authors.lastname: Angelini
authors.forename: A
authors.initials: A
authors.lastname: Spadano
authors.forename: D
authors.initials: D
authors.lastname: Natale
authors.forename: A
authors.initials: A
authors.lastname: Berardi
mesh_terms: D000293:Adolescent; D000328:Adult; D001804:Blood Transfusion, Autologous / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008875:Middle Aged